Comprehensive and Diversified Monoclonal Antibody Pipeline



1. Phase 2 clinical trials are not required for biosimilars.
2. Our Phase 3 clinical trial for HLX01 focused on the treatment of CD20-positive diffuse large B cell lymphoma, which is the most common subtype of NHL. HLX01's reference drug, MabThera, is approved in China for three NHL subtypes (namely DLBCL, relapsed or refractory follicular central lymphoma and previously-untreated CD20-positive stage III-IV follicular lymphoma). HLX01 is also approved for these three indications.
3. Argentina, Paraguay, Uruguay and Bolivia.
4. Our Phase 3 clinical trial for HLX02 focuses on the treatment of HER2+ metastatic breast cancer. As HLX02's reference drug, Herceptin, is approved in China for HER2+ early breast cancer, HER2+ metastatic breast cancer and HER2+ metastatic gastric cancer, our NDA in China seeks approval for all three indications for HLX02. Our commercialization partner Accord filed an MAA with the EMA for these three indications and gastroesophageal junction cancer. Subject enrolment of the Phase 3 clinical trial for HLX02 has been completed. While HLX02 is still undergoing Phase 3 clinical trial, our NDA for HLX02 was accepted by the NMPA in April 2019 and is currently under its priority review.
5. Over 70 jurisdictions and regions in Europe, MENA and CIS.
6. Australia, New Zealand, Colombia and Malaysia.
7. Our Phase 3 clinical trial for HLX03 focuses on the treatment of plaque psoriasis. As HLX03's reference drug, Humira, is approved in China for plaque psoriasis, rheumatoid arthritis and ankylosing spondylitis, we have filed for NDA approval for all three indications for HLX03. We have completed the Phase 3 clinical trial for HLX03. Our NDA for HLX03 was accepted by the NMPA in January 2019 and is currently under its priority review.
8. Our Phase 3 clinical trial for HLX04 focuses on the treatment of mCRC. As HLX04's reference drug, Avastin, is approved in China for mCRC and unresectable, locally advanced, recurrent or metastatic nsNSCLC, we plan to seek NDA approval for both indications for HLX04.
9. Licensed out to Shanghai Jingze.
10. Includes advanced gastric cancer, gastroesophageal junction adenocarcinoma, NSCLC and mCRC.
11. Considered a bio-innovative product because the originator product has not been approved for the relevant indication yet in China.
12. Greater China and certain countries in Southeast, Central and South Asia.
13. We do not consider HLX07, HLX10, HLX04 + HLX10 combination therapy and HLX10 + Chemo combination therapy to be our Core Products as (i) data on Phase 1 clinical trials for HLX07, HLX10 and HLX04 + HLX10 combination therapy have not become available, and (ii) data on Phase 3 clinical trials for HLX10 + Chemo, which do not require Phase 1 clinical trials, have not become available. We are also developing HLX10 to treat Hepatitis B virus.

Henlius

Henlius Differentiation Highlights

1 Fully-Integrated & Efficient Global R&D Platforms

- ✓ **In-house** R&D Platforms Covering Whole Processes
- ✓ **Global** Synergy of 3 R&D sites
- ✓ **Fast-follow** de-risk strategy
- ✓ **$220M** high-efficient R&D investment

2 Capable to Enter Global Main Regulatory Markets

- ✓ **International** Quality Standard
- ✓ **Strong** RA & Clinical Medical Team
- ✓ **31 INDs** obtained across six jurisdictions

3 Market Penetration Speed

- ✓ **6** Blockbusters go to market in **3** years
- ✓ **3-4** products will be first-entry to Chinese markets

4 Fosun/Fosun pharma's Support

- ✓ R&D **Capital** investment
- ✓ **Market Access** & **Sales** resources
- ✓ **Government** Affairs
- ✓ **Synergy** in Strategy and Culture

5 High-level Expert Team

- ✓ Sr. Management Team hold **20+y** of industry experiences covering entire value-chains
- ✓ **79** senior industry experts
  - **67%** 10+y of Industry Experiences
  - **62%** Oversea Experiences